Theriva Biologics, Inc. Income Statement
TOVX|1 years of annual SEC 10-K data (FY2011-FY2011)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
Theriva Biologics, Inc. reported $3M in revenue and $2M in net loss for FY2011. Its profit margin was -65.5% in FY2011.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.80 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2011 |
|---|---|
| Revenue | $2.6M |
| SG&A Expense | $2.1M |
| R&D Expense | $1.6M |
| Net Income | -$1.7M |
| EPS (Diluted) | -$0.08 |
| Shares Outstanding | 23.3M |
| Profit Margin | -65.5% |